KBC Group
MCRB icon

KBC Group’s Seres Therapeutics MCRB Stock Holding History

KBC Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-262
Closed -$36K – 1314
2021
Q3 		$36K Sell
262
-302
-54% -$59.1K ﹤0.01% 1262
2021
Q2 		$270K Buy
564
+490
+662% +$207K ﹤0.01% 1134
2021
Q1 		$30K Hold
74
– – ﹤0.01% 1279
2020
Q4 		$199K Sell
74
-30
-29% -$17.6K ﹤0.01% 1252
2020
Q3 		$58K Sell
104
-635
-86% -$211K ﹤0.01% 1203
2020
Q2 		$70K Buy
739
+219
+42% +$19.2K ﹤0.01% 1240
2020
Q1 		$37K Hold
520
– – ﹤0.01% 1218
2019
Q4 		$36K Buy
520
+513
+7,329% +$38K ﹤0.01% 1432
2019
Q3 		$1K Hold
7
– – ﹤0.01% 1476
2019
Q2 		$1K Buy
+7
New +$664 ﹤0.01% 1455

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

KBC Group's MCRB Position: Q4 2021 in Review

KBC Group sold out of Seres Therapeutics (MCRB) in Q4 2021, closing a stake of 262 shares — an estimated $36K sold.

KBC Group first reported a position in MCRB in Q2 2019 and held it in 10 quarters. The position peaked at $270K in Q2 2021. 148 funds tracked by Wall St. Rank hold MCRB as of Q4 2021.

  • KBC Group reported no remaining Seres Therapeutics position as of Q4 2021 after selling out during the quarter.
  • KBC Group sold 262 Seres Therapeutics shares in Q4 2021, an estimated $36K.
  • KBC Group first reported a position in Seres Therapeutics in Q2 2019 and held it in 10 quarters.
  • KBC Group's Seres Therapeutics position peaked at $270K in Q2 2021.
  • 148 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2021.

Based on KBC Group's 13F filing for Q4 2021, filed 3 Feb 2022.